Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques
Christiane Stahl-Hennig, Martin Eisenblätter, Edith Jasny, Tamara Rzehak, Klara Tenner-Racz, Christine Trumpfheller, Andres M Salazar, Klaus Uberla, Karen Nieto, Jürgen Kleinschmidt, Reiner Schulte, Lutz Gissmann, Martin Müller, Anna Sacher, Paul Racz, Ralph M Steinman, Mariagrazia Uguccioni, Ralf Ignatius, Christiane Stahl-Hennig, Martin Eisenblätter, Edith Jasny, Tamara Rzehak, Klara Tenner-Racz, Christine Trumpfheller, Andres M Salazar, Klaus Uberla, Karen Nieto, Jürgen Kleinschmidt, Reiner Schulte, Lutz Gissmann, Martin Müller, Anna Sacher, Paul Racz, Ralph M Steinman, Mariagrazia Uguccioni, Ralf Ignatius
Abstract
Toll-like receptor (TLR) ligands are being considered as adjuvants for the induction of antigen-specific immune responses, as in the design of vaccines. Polyriboinosinic-polyribocytoidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA), is recognized by TLR3 and other intracellular receptors. Poly ICLC is a poly I:C analogue, which has been stabilized against the serum nucleases that are present in the plasma of primates. Poly I:C(12)U, another analogue, is less toxic but also less stable in vivo than poly I:C, and TLR3 is essential for its recognition. To study the effects of these compounds on the induction of protein-specific immune responses in an animal model relevant to humans, rhesus macaques were immunized subcutaneously (s.c.) with keyhole limpet hemocyanin (KLH) or human papillomavirus (HPV)16 capsomeres with or without dsRNA or a control adjuvant, the TLR9 ligand CpG-C. All dsRNA compounds served as adjuvants for KLH-specific cellular immune responses, with the highest proliferative responses being observed with 2 mg/animal poly ICLC (p = 0.002) or 6 mg/animal poly I:C(12)U (p = 0.001) when compared with immunization with KLH alone. Notably, poly ICLC -- but not CpG-C given at the same dose -- also helped to induce HPV16-specific Th1 immune responses while both adjuvants supported the induction of strong anti-HPV16 L1 antibody responses as determined by ELISA and neutralization assay. In contrast, control animals injected with HPV16 capsomeres alone did not develop substantial HPV16-specific immune responses. Injection of dsRNA led to increased numbers of cells producing the T cell-activating chemokines CXCL9 and CXCL10 as detected by in situ hybridization in draining lymph nodes 18 hours after injections, and to increased serum levels of CXCL10 (p = 0.01). This was paralleled by the reduced production of the homeostatic T cell-attracting chemokine CCL21. Thus, synthetic dsRNAs induce an innate chemokine response and act as adjuvants for virus-specific Th1 and humoral immune responses in nonhuman primates.
Conflict of interest statement
AMS is the CEO of Oncovir, Inc., which provided the poly ICLC for the current study. He was not involved in the acquisition and analysis of the data. All other authors declare they have no competing interests.
Figures
References
- Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000;406:793–798.
- Kwissa M, Amara RR, Robinson HL, Moss B, Alkan S, et al. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med. 2007;204:2733–2746.
- McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227–255.
- Brave A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol Pharm. 2007;4:18–32.
- Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. 2006;203:607–617.
- McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27:687–690.
- Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769–779.
- Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199:815–824.
- Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198:267–279.
- Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607–1618.
- HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20(Suppl 3):S34–S39.
- Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–559.
- Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007;5:505–517.
- Hartmann G, Marschner A, Viveros PR, Stahl-Hennig C, Eisenblatter M, et al. CpG oligonucleotides induce strong humoral but only weak CD4(+) T cell responses to protein antigens in rhesus macaques in vivo. Vaccine. 2005;23:3310–3317.
- Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863–869.
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252.
- Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732–738.
- Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004;101:17264–17269.
- Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem (Tokyo) 2007;141:137–145.
- Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc Natl Acad Sci U S A. 1969;64:81–86.
- Thomson AW. The influence of poly I: poly C on kinetics of the primary immune response to sheep erythrocytes in the mouse spleen. Biomedicine. 1977;26:319–326.
- Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 2005;79:2910–2919.
- Partidos CD, Hoebeke J, Moreau E, Chaloin O, Tunis M, et al. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol. 2005;35:1521–1529.
- Sloat BR, Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine. 2006;24:6405–6413.
- Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A. 2006;103:8459–8464.
- Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101–105.
- Nordlund JJ, Wolff SM, Levy HB. Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med. 1970;133:439–444.
- Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975;132:434–439.
- Sammons ML, Stephen EL, Levy HB, Baron S, Hilmas DE. Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother. 1977;11:80–83.
- Levy HB, London W, Fuccillo DA, Baron S, Rice J. Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine. J Infect Dis. 1976;133(Suppl):A256–A259.
- Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, et al. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis. 1977;136:122–126.
- Stephen EL, Hilmas DE, Levy HB, Spertzel RO. Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis. 1979;139:267–272.
- Purcell RH, London WT, McAuliffe VJ, Palmer AE, Kaplan PM, et al. Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet. 1976;2:757–761.
- Puri SK, Dutta GP, Levy HB, Maheshwari RK. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. J Interferon Cytokine Res. 1996;16:49–52.
- Houston WE, Crabbs CL, Stephen EL, Levy HB. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun. 1976;14:318–319.
- Stephen EL, Hilmas DE, Mangiafico JA, Levy HB. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science. 1977;197:1289–1290.
- Champney KJ, Levine DP, Levy HB, Lerner AM. Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun. 1979;25:831–837.
- Durie BG, Levy HB, Voakes J, Jett JR, Levine AS. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J Biol Response Mod. 1985;4:518–524.
- Lampkin BC, Levine AS, Levy H, Krivit W, Hammond D. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res. 1985;45:5904–5909.
- Stevenson HC, Abrams PG, Schoenberger CS, Smalley RB, Herberman RB, et al. A phase I evaluation of poly(I,C)-LC in cancer patients. J Biol Response Mod. 1985;4:650–655.
- Krown SE, Kerr D, Stewart WE, II, Field AK, Oettgen HF. Phase I trials of poly(I,C) complexes in advanced cancer. J Biol Response Mod. 1985;4:640–649.
- McFarlin DE, Bever CT, Salazar AM, Levy HB. A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod. 1985;4:544–548.
- Bever CT, Jr, Salazar AM, Neely E, Ferraraccio BE, Rose JW, et al. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology. 1986;36:494–498.
- Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery. 1996;38:1096–1103. Discussion 1103–1094.
- Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007;196:1313–1320.
- Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect. 2007;9:1333–1340.
- Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis. 1996;15:580–587.
- Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med. 2006;203:1249–1258.
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
- Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007;177:469–479.
- Proost P, Vynckier AK, Mahieu F, Put W, Grillet B, et al. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol. 2003;33:3146–3153.
- Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci U S A. 2000;97:12694–12699.
- Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol. 2007;178:5200–5208.
- Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A. 2008;105:2574–2579.
- Thones N, Herreiner A, Schadlich L, Piuko K, Muller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol. 2008;82:5472–5485.
- Jasny E, Eisenblatter M, Matz-Rensing K, Tenner-Racz K, Tenbusch M, et al. IL-12-impaired and IL-12-secreting dendritic cells produce IL-23 upon CD154 restimulation. J Immunol. 2008;180:6629–6639.
- Mehlhop E, Villamide LA, Frank I, Gettie A, Santisteban C, et al. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J Immunol Methods. 2002;260:219–234.
- Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14:461–470.
- Fujimoto C, Nakagawa Y, Ohara K, Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol. 2004;16:55–63.
- Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433:887–892.
- Durand V, Wong SY, Tough DF, Le Bon A. IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists. Vaccine. 2006;24(Suppl 2):S22–S23.
- Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199:775–784.
- Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996;272:1947–1950.
- Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28:220–228.
- Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.
- Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006;24:5119–5132.
- Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:963–969.
- Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol. 2001;158:1703–1711.
- Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005;175:788–795.
- Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity. 2000;12:483–494.
- Hsieh MF, Lai SL, Chen JP, Sung JM, Lin YL, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol. 2006;177:1855–1863.
- Widney DP, Xia YR, Lusis AJ, Smith JB. The murine chemokine CXCL11 (IFN-inducible T cell alpha chemoattractant) is an IFN-gamma- and lipopolysaccharide-inducible glucocorticoid-attenuated response gene expressed in lung and other tissues during endotoxemia. J Immunol. 2000;164:6322–6331.
- Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol. 2004;172:7417–7424.
- Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168:3195–3204.
- Rabin RL, Alston MA, Sircus JC, Knollmann-Ritschel B, Moratz C, et al. CXCR3 is induced early on the pathway of CD4+ T cell differentiation and bridges central and peripheral functions. J Immunol. 2003;171:2812–2824.
- Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol. 2007;178:5271–5276.
- Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A. 2004;101:10116–10121.
- Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, et al. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol. 2004;172:138–143.
- Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, et al. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol. 2006;176:1348–1354.
- Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini JC, et al. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol. 2006;177:8708–8713.
- Stevenson HC, Dekaban GA, Miller PJ, Benyajati C, Pearson ML. Analysis of human blood monocyte activation at the level of gene expression. Expression of alpha interferon genes during activation of human monocytes by poly IC/LC and muramyl dipeptide. J Exp Med. 1985;161:503–513.
- Pirhonen J, Siren J, Julkunen I, Matikainen S. IFN-{alpha} regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol. 2007;82:1185–1192. E-pub August 7.
- Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065–6073.
- Bever CT, Jr, Jacobson S, Mingioli ES, McFarland HF, McFarlin DE, et al. Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. Int J Immunopharmacol. 1991;13:613–618.
- Lebre MC, Antons JC, Kalinski P, Schuitemaker JH, van Capel TM, et al. Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18. J Invest Dermatol. 2003;120:990–997.
- Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol. 2005;79:12893–12904.
- Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann MF, et al. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science. 2007;317:670–674.
- Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, et al. Chimeric papillomavirus-like particles. Virology. 1997;234:93–111.
- Stahl-Hennig C, Eisenblatter M, Franz M, Stoiber H, Tenner-Racz K, et al. A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum. Front Biosci. 2007;12:2107–2123.
- Gasparic M, Rubio I, Thönes N, Gissmann L, Müller M. Prophylactic DNA immunization against multiple papillomavirus types. Vaccine. 2007;25:4540–4553.
- Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol. 2005;35:1347–1359.
- Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest. 1999;104:R49–54.
Source: PubMed